Top Globe News – Lifestyle
Author:
Immutep Limited
Immutep Receives Nasdaq Notice of Bid Price Deficiency
April 30, 2026
Immutep Quarterly Activities Report Q3 FY26
April 30, 2026
Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
April 29, 2026
Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma
April 15, 2026
Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases
March 19, 2026
TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis
March 13, 2026